Honasa Consumer Acquires Majority Stake In Fluence Pharma For ₹135 Cr

Why It Matters

The acquisition gives Honasa a foothold in India’s fast‑growing nutraceutical sector, diversifying revenue streams and supporting its multi‑brand growth strategy aimed at double‑digit expansion.

Key Takeaways

• Honasa pays ₹135 Cr ($16 M) for 58% of Fluence Pharma.
• Fluence posted FY25 turnover ₹37.2 Cr ($4.5 M), up 3% YoY.
• Honasa will launch Honasa Health subsidiary with ₹1 L paid‑up capital.
• Remaining 42% stake to be bought in two tranches over 5‑7 years.
• India's nutraceutical market estimated at ₹16,000 Cr ($1.9 B).

Pulse Analysis

India’s nutraceutical market is on a rapid ascent, driven by rising consumer awareness of preventive health and a preference for “inside‑out” beauty solutions. Analysts peg the sector at roughly ₹16,000 Cr ($1.9 B) today, with double‑digit growth expected through 2030. This backdrop makes the Honasa‑Fluence deal a timely entry into a high‑margin, science‑backed category that complements the company’s existing skin‑care and hair‑care offerings.

Honasa’s strategic pivot to a house‑of‑brands model has already yielded a series of acquisitions across beauty, grooming and oral‑care. By integrating Fluence’s patented Cyclical Nutrition Therapy (CNT) with its robust distribution network and digital marketing expertise, Honasa can accelerate product development and reach consumers directly through both online channels and its expanding offline footprint. The creation of Honasa Health as a dedicated subsidiary underscores the firm’s intent to build a full‑stack nutraceutical business, from formulation to B2C sales, leveraging the existing dermatologist and trichologist network that Fluence has cultivated.

Financially, the move dovetails with Honasa’s “Honasa 3.0” roadmap, which targets a FY31 revenue of over ₹5,500 Cr ($660 M) and EBITDA margins above 15%. The acquisition not only adds a new revenue stream—projected to contribute several hundred crores in the next five years—but also reduces reliance on the flagship Mamaearth brand. With a recent profit surge of 175% and a 15.7% rise in operating revenue, Honasa is positioned to fund the phased purchase of the remaining Fluence equity while scaling its broader multi‑brand ambitions.